Invivyd forms SPEAR Study Group with top researchers to test mAbs for Long COVID

Invivyd, Inc.

SPEAR Study Group includes Drs. Michael Peluso, Amy Proal, David Putrino; will evaluate PEMGARDA and VYD2311.
Up to 5% of Americans report Long COVID symptoms; no approved treatments exist for the condition.
PEMGARDA currently authorized only for COVID-19 prophylaxis; not approved for Long COVID treatment.
Invivyd plans FDA meeting early 3Q 2025 to discuss rapid approval pathways for COVID-19 mAbs.
Anecdotal reports suggest pemivibart may relieve Long COVID symptoms; rigorous clinical trials are planned.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.